News for Jaguar Health Stock (JAGX)

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

Accesswire • Tuesday

Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript

Seeking Alpha • 11/15/24

Jaguar Health Reports Third Quarter 2024 Financial Results

Accesswire • 11/13/24

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates

Accesswire • 11/11/24

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs

Accesswire • 11/06/24

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)

Accesswire • 11/04/24

Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting

Accesswire • 10/29/24

Small-cap biotech Jaguar Health's stock jumps 7% as it launches treatment for oral mucositis in cancer patients

Market Watch • 10/16/24

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.

Accesswire • 10/16/24

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Accesswire • 10/11/24

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

Accesswire • 10/10/24

Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial

Accesswire • 10/08/24

Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer

Accesswire • 10/01/24

Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Survivors

Accesswire • 09/26/24

Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Accesswire • 09/25/24

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch

Accesswire • 09/24/24

Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference

Accesswire • 09/16/24

Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

Accesswire • 09/10/24

Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference

Accesswire • 09/06/24

Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

Accesswire • 09/05/24

New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company's Near-Term Commercial & Development Milestones

Accesswire • 09/04/24

Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

Accesswire • 08/27/24

Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award

Accesswire • 08/20/24

Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

Accesswire • 08/19/24

Jaguar Health, Inc. (JAGX) Q2 2024 Earnings Call Transcript

Seeking Alpha • 08/13/24